“Hormone Healing”的搜索结果，显示 1-10 项，共有 2729 项

  1. Metastatic castration-resistant prostate cancer (mCRPC)

    Treatments aren't likely to cure the cancer. Options may include hormone therapy, chemotherapy, targeted therapy, radiopharmaceutical treatments, immunotherapy ...

  2. Transsphenoidal surgery

    The pituitary gland is a small, pea-sized gland in the skull behind the nose. It manages hormone levels in the body. Small noncancerous tumors, also called ...

  3. Metastatic castration-resistant prostate cancer (mCRPC) - 诊断与治疗- 妙佑医疗国际

    Learn about treatments for prostate cancer that no longer responds to hormone therapy. Options include chemotherapy, radiopharmaceutical therapy and others.

  4. 前列腺癌激素治疗- 妙佑医疗国际

    Hormone therapy for prostate cancer. National Cancer Institute. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet. Accessed May 27 ...

  5. 疼痛康复中心- 临床试验- 妙佑医疗国际

    The purpose of this study is to evaluate the hormonal profile related to opioid-induced hypogonadism (OIH) in chronic pain patients before and after ...

  6. Prostate cancer recurrence

    Treatments may offer the chance for a cure. When ... Hormone therapy is often combined with chemotherapy. ... Hormone therapy. Hormone therapy for ...

  7. Chemotherapy for prostate cancer - 妙佑医疗国际

    It also may help treat advanced prostate cancer when hormone therapy isn't working. ... hormones and uses the hormones to grow. ... Chemotherapy does not cure ...

  8. Prostate cancer recurrence - 诊断与治疗- 妙佑医疗国际

    Treatments may offer the chance for a cure. When ... Treatment often starts with medicines to block the hormones that prostate cancer cells use to help them grow.

  9. 生物等同激素：是否更安全？ - 妙佑医疗国际

    Clinical Consensus No. 6: Compounded bioidentical menopausal hormone therapy. Obstetrics & Gynecology. 2023; doi:10.1097/AOG.0000000000005395. American College ...

  10. 关于 - 妙佑医疗国际

    ... hormone therapy to lower levels of testosterone or dihydrotestosterone. This ... Cure rates are very high, especially in people with low- and intermediate-risk ...